Neuropore Therapeutics Gets $20M Milestone Payment

San Diego-based Neuropore Therapies, which is developing treatments for Parkinson's disease, reported today that it has received $20M in a milestone payment from UCB. Neuropore Therapeutics said the payment is related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson's Disease. Doug Bonhaus is President and CEO of Neuropore Therapies. UCB is based in Belgium.